<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We recently discovered the <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo>-associated <z:e sem="disease" ids="C0019340" disease_type="Disease or Syndrome" abbrv="">herpes</z:e> virus (KSHV/HHV-8) in an uncommon and unusual subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:hpo ids='HP_0002665'>lymphomas</z:hpo> that grow mainly in the body cavities as lymphomatous effusions without an identifiable contiguous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass </plain></SENT>
<SENT sid="1" pm="."><plain>The consistent presence of KSHV and certain other distinctive features of these body cavity-based <z:hpo ids='HP_0002665'>lymphomas</z:hpo> suggest that they represent a distinct entity </plain></SENT>
<SENT sid="2" pm="."><plain>We tested this hypothesis by investigating 19 malignant lymphomatous effusions occurring in the absence of a contiguous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass for their clinical, morphologic, immunophenotypic, <z:mp ids='MP_0001799'>viral</z:mp>, and molecular characteristics, KSHV was present in 15 of 19 <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> four KSHV-negative lymphomatous effusions exhibited Burkitt or Burkitt-like <z:mp ids='MP_0000002'>morphology</z:mp> and c-myc gene rearrangements and, therefore, appeared to be Burkitt-type <z:hpo ids='HP_0002665'>lymphomas</z:hpo> occurring in the body cavities </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, <z:hpo ids='HP_0000001'>all</z:hpo> 15 KSHV-positive lymphomatous effusions exhibited a distinctive <z:mp ids='MP_0000002'>morphology</z:mp> bridging large-cell <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and anaplastic large-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:hpo ids='HP_0000001'>all</z:hpo> 12 cases studied lacked c-myc gene rearrangements </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, these <z:hpo ids='HP_0002665'>lymphomas</z:hpo> occurred in men (15/15), frequently but not exclusively in association with <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> (13/15), in which homosexuality was a risk factor (13/13), presented initially as a lymphomatous effusion (14/15), remained localized to the body cavity of origin (13/15), expressed CD45 (15/15) and one or more activation-associated antigens (9/10) in the frequent absence of B-cell-associated antigens (11/15), exhibited clonal immunoglobulin gene rearrangements (13/13), contained Epstein-Barr virus (14/15), and lacked bcl-2, bcl-6, ras and p53 gene alterations (13/15) </plain></SENT>
<SENT sid="6" pm="."><plain>These findings strongly suggest that the KSHV-positive malignant lymphomatous effusions represent a distinct clinicopathologic and biologic entity and should be distinguished from other malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> occurring in the body cavities </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, we recommend that these malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> be designated primary effusion <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (PEL), rather than body cavity-based <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, since this term describes them more accurately and avoids their <z:hpo ids='HP_0001289'>confusion</z:hpo> with other malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> that occur in the body cavities </plain></SENT>
<SENT sid="8" pm="."><plain>We further recommend that these PEL be considered for inclusion as a new entity in the Revised European-American <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> Classification </plain></SENT>
</text></document>